KRN-101 for Cancer-Related Distress

This study will investigate the effects of KRN-101 (a psilocybin-based medicine) in participants with cancer-related distress.

Topic Anxiety Depression
Compound Psilocybin
Country United Kingdom
Visit trial
Status Planned
Results Published
Chance of happening 69%
Phase Phase II
Design Open
Type Interventional
Generation Second
Sex All
Therapy No

Trial Details



NCT Number

Sponsors & Collaborators

Albert Labs
Albert Labs is a publicly listed company (CSE) that uses Real-World Evidence (RWE) to accelerate the psychedelic drug development process.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.